Ketamine suppresses hypoxia-induced inflammatory responses in the late-gestation ovine fetal kidney cortex.
Acute fetal hypoxia is a form of fetal stress that stimulates renal vasoconstriction and ischaemia as a consequence of the physiological redistribution of combined ventricular output. Because of the potential ischaemia-reperfusion injury to the kidney, we hypothesized that it would respond to hypoxia with an increase in the expression of inflammatory genes, and that ketamine (an N-methyl-D-aspartate receptor antagonist) would reduce or block this response. Hypoxia was induced for 30 min in chronically catheterized fetal sheep (125 ± 3 days), with or without ketamine (3 mg kg(-1)) administered intravenously to the fetus 10 min prior to hypoxia. Gene expression in fetal kidney cortex collected 24 h after the onset of hypoxia was analysed using ovine Agilent 15.5k array and validated with qPCR and immunohistochemistry in four groups of ewes: normoxic control, normoxia + ketamine, hypoxic control and hypoxia + ketamine (n = 3-4 per group). Significant differences in gene expression between groups were determined with t-statistics using the limma package for R (P ≤ 0.05). Enriched biological processes for the 427 upregulated genes were immune and inflammatory responses and for the 946 downregulated genes were metabolic processes. Ketamine countered the effects of hypoxia on upregulated immune/inflammatory responses as well as the downregulated metabolic responses. We conclude that our transcriptomics modelling predicts that hypoxia activates inflammatory pathways and reduces metabolism in the fetal kidney cortex, and ketamine blocks or ameliorates this response. The results suggest that ketamine may have therapeutic potential for protection from ischaemic renal damage.
Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL, 32610-0274, USA.
Eileen I
EI
Chang
Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL, 32610-0274, USA.
Miguel A
MA
Zárate
Department of Animal Reproduction, Universidad Nacional de Río Cuarto, Río Cuarto, Córdoba, Argentina.
Maria B
MB
Rabaglino
Department of Pharmacodynamics, University of Florida College of Pharmacy, Gainesville, FL, 32610-0487, USA.
Elaine M
EM
Richards
Department of Pharmacodynamics, University of Florida College of Pharmacy, Gainesville, FL, 32610-0487, USA.
Maureen
M
Keller-Wood
Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL, 32610-0274, USA.
Charles E
CE
Wood
D000818:Animals; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D005311:Fetal Hypoxia / Q000188:drug therapy*; D007249:Inflammation / Q000188:drug therapy; D007378:Interleukins / Q000235:genetics / Q000378:metabolism; D007649:Ketamine / Q000627:therapeutic use*; D007668:Kidney / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology*; D011247:Pregnancy; D012756:Sheep
D018925:Chemokines; D018691:Excitatory Amino Acid Antagonists; D007378:Interleukins; D007649:Ketamine